Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
REL
REST API REST API
Homo sapiens
REL is differentially expressed in 230 experiments: 101 organism parts: tonsil, lung, ... (99 more);, 150 disease states: normal, Burkitt's lymphoma, ... (148 more);, 78 cell types 262 cell lines 49 compound treatments and 64 other conditions.
Synonyms c-Rel, I-Rel
Orthologs REL (Bos taurus)   REL (Gallus gallus)   Rel (Rattus norvegicus)   Rel (Mus musculus)   rel (Danio rerio)   Dif (Drosophila melanogaster)   dl (Drosophila melanogaster)   rel (Xenopus laevis)   REL (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, nucleus, positive regulation of transcription, DNA-dependent, positive regulation of I-kappaB kinase/NF-kappaB cascade, positive regulation of interleukin-12 biosynthetic process, cytokine production, sequence-specific DNA binding transcription factor activity
InterPro Term RHD, NF_Rel_dor, IPT_TIG_rcpt
UniProt Accession Q17RU2, Q04864
Search EB-eye ENSG00000162924
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-1563, E-TABM-130, E-TABM-145, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (30 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
DU145
2
E-GEOD-20089, E-GEOD-17482
RD
1
E-MTAB-37
cultured
1
E-MTAB-62
BC-2
1
E-GEOD-2149
SKUT1
1
E-MTAB-37
256 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-20677, E-GEOD-13909, ... (35 experiments)

Factor Value U/D Experiments
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
mononuclear cell
2
E-GEOD-6053, E-GEOD-7307
adipocyte
2
E-AFMX-5, E-TABM-145
2
E-TABM-145, E-TABM-130
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
72 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-MEXP-2069, E-GEOD-22148, ... (38 experiments)

Factor Value U/D Experiments
gastric carcinoma
2
E-GEOD-15460, E-GEOD-2685
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
small cell cancer
1
E-MTAB-62
ulcerative colitis
1
E-GEOD-3365
cellulitis
1
E-MTAB-62
144 more value(s).


Compound treatment

studied in E-GEOD-697, E-GEOD-3720, E-TABM-868, E-MEXP-1958, E-MEXP-941, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
4
E-GEOD-3720, E-TABM-868, E-MEXP-1958, E-GEOD-2706
propofol
1
E-GEOD-4386
vanadium pentoxide
1
E-GEOD-5339
filtered air
1
E-TABM-127
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
43 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
41
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cd3
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-TABM-255, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-GEOD-19246, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-21750, E-TABM-868, E-TABM-601, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-10315, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, E-TABM-26, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980, E-GEOD-6802, E-GEOD-512, E-GEOD-360 ... (5 experiments)

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-1460, E-GEOD-3982 ... (5 experiments)

Population
studied in E-GEOD-4922

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.37 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM